Support
Super User

Super User

Sunday, 08 August 2021 11:20

Jennifer Friedmann

Sunday, 08 August 2021 11:20

Khalil Sultanem

Sunday, 08 August 2021 11:20

Aksa Anwar

Sunday, 08 August 2021 11:20

Rachael M Morgan

Sunday, 08 August 2021 11:20

snigdha nutalapati

Sunday, 08 August 2021 11:20

Aliyah Pabani

Sunday, 08 August 2021 11:20

Danyang Zheng

Sunday, 08 August 2021 11:20

Xiao Hu

Sunday, 08 August 2021 11:20

Dirk De Ruysscher

Dr. De Ruysscher earned his medical degree at the University of Leuven, Belgium, in 1986, and became Radiation Oncologist at the same university in 1991. In 1992, he obtained his PhD thesis at the University of Leuven on the influence of radiotherapy on immunity. At present, Dr. De Ruysscher is full Professor of Radiation Oncology/ Respiratory Oncology at the Maastricht University Medical Center, Maastricht, The Netherlands.
He heads of the Division Maastro Clinical Research, Chairs the Dutch Platform for Radiotherapy of Lung Cancer, chairs DUPROTON (the Dutch organization for proton therapy research) and chairs the EORTC Lung Cancer Group/ Oligometastatic and new development group.
He is the coordinator of the biobank project at Maastro Clinic that was able to include about 10000 patients for radiogenomic studies.
He was or is the study coordinator of seven phase I trials, twenty-one phase II trials, six phase III trials and one observational study, dealing with individualized radiation-dose escalation, combining targeted agents with radiotherapy, the development of new PET tracers, molecular pathways involved in radiation damage, individualized radiotherapy, proton therapy, meta-analyses, cost-effectiveness, radiomics, immune therapy and prophylactic cranial irradiation.
In 2019, he received the ESTRO Claudius Regaud Gold Medal.
Dr. De Ruysscher published over 400 peer-reviewed Wi-1 papers and chapters in several scientific books.
Sunday, 08 August 2021 11:20

Haiyan Zeng

Page 151 of 518